Tandem Nano Ltd (TNL) is a University of Liverpool start-up focused on the development of its proprietary Solid Drug Nanoparticle technology platform.
This dynamic, inter-disciplinary team aims to improve oral medications and develop novel long- acting medicines that may provide months of protection or therapy from a single injection.
The move to Liverpool Science Park marks an important milestone in the newly- formed company’s progression.
Prof Steve Rannard, CTO at Tandem Nano, commented:
“Locating TNL operations into the Science Park is another clear sign of the continual progress of the company and our delivery of new innovations to the pharmaceutical and non-pharma sectors.”
Prof Andrew Owen, CSO at Tandem Nano, also added:
“Long-acting drug delivery holds great promise for treatment and prophylaxis of complex indications. We are excited to be embarking upon a new phase in the company’s development through our move.”
The platform holds the potential to transform the scope of drug delivery and hopes to pave the way towards better access to medicines in low and middle-income countries, a key mission that is strongly aligned to TNL.
The team is now working with a number of major companies across several application areas from pharmaceuticals to agriculture and look forward to engaging with the vibrant community at Liverpool Science Park.
For more information about Tandem Nano, please visit their website